Stock comparison
IDEXX Laboratories
Phibro Animal Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
PAHC
Phibro Animal Health
Market cap
$1.47B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | PAHC | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 41D | IDXX |
| Benjamin Graham | 72B | 74B | PAHC |
| Philip Fisher | 67B | 25F | IDXX |
| Peter Lynch | 63C | 29F | IDXX |
| Joel Greenblatt | 75B | 38D | IDXX |
| Charlie Munger | 79B | 36D | IDXX |
| Terry Smith | 76B | 32F | IDXX |
Side-by-side metrics
| Metric | IDXX | PAHC |
|---|---|---|
| Market cap | $42.11B | $1.47B |
| P/E (TTM) | 39.0x | 15.5x |
| EV/EBIT | 31.6x | 20.0x |
| ROIC (TTM) | 40.66% | 11.17% |
| Gross margin | 62.05% | 32.54% |
| Net margin | 24.63% | 6.35% |
| Revenue CAGR 5y | 7.56% | 11.68% |
| EPS CAGR 5y | 10.79% | -2.92% |
| Debt / Equity | 0.7x | 2.2x |
| Dividend yield | 0.0% | 1.32% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -2.92%+127%
- Market cap$42.11Bvs $1.47B+97%
- Net margin24.63%vs 6.35%+74%
- ROIC (TTM)40.66%vs 11.17%+73%
PAHC leads on
- Dividend yield1.32%vs 0.0%+100%
- P/E (TTM)15.5xvs 39.0x+60%
- EV/EBIT20.0xvs 31.6x+37%
- Revenue CAGR 5y11.68%vs 7.56%+35%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.